Just - Evotec Biologics' J.MD^TM suite of technologies analyse and optimize antibody candidates prior to clinical development and enable the lead selection of highly developable and manufacturable candidates.

Assessing developability and manufacturability during the selection process allows:

• Shorter timelines with lower development and manufacturing costs

• Identification of lead candidates having a better fit to existing manufacturing platforms

• Less time spent solving technical issues during process development

• Fewer liabilities which could degrade the therapeutic efficacy leading to longer shelf life and improved serum stability